MARATTO

article · SVU-International Journal of Medical Sciences

Role of Growth Differentiation Factor15 in pediatric cardiac patients

20242 citationsOpen accessSouth Valley University

Abstract

Background: The most common kind of birth abnormality is a heart problem. When the heart doesn't form properly during pregnancy or birth, it's called a congenital heart defect. CHDs are associated with high rates of mortality and disability. Multiple processes are controlled by the cytokine growth differentiation factor-15 (GDF-15). Because of its continuous overexpression in both CVD and diabetes, GDF-15 is recommended as a biomarker for the existence and severity of both illnesses. In contrast, a large body of research indicates that GDF-15 has a protective role in the regulation of inflammation, endothelial cell function, insulin sensitivity, and weight gain, and is cardioprotective in myocardial infarction (MI). Objectives: Aim of the work is to give highlight on (GDF15) in pediatric cardiac diseases of varies aetiologies. Conclusion: It has been discovered that the cytokine growth differentiation factor-15 (GDF-15) is elevated in a number of clinical states, including hypertension, cardiovascular illness, and oxygen deprivation. GDF-15 is also found to be elevated in HF and PH (pulmonary hypertension). An increased level of GDF-15 is seen in newborns and children with PH-CHD, suggesting its use as a diagnostic biomarker.

Research topics

  • GDF15 and Related Biomarkers
  • Apelin-related biomedical research
  • Nutrition and Health in Aging

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/svuijm.2022.164871.1416

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.